Botulinum Toxin Market by Product (Toxin Type A and Toxin Type B), by Application (Therapeutic and Aesthetic), by Gender (Male and Female), by Age Group (13-19, 20-29, 30-39, 40-54, 55 and above), and by End-User (Hospitals, Dermatology Clinics, and Spas & Cosmetic Centers) - Global Opportunity Analysis and Industry Forecast 2022-2030

Market Definition:

The global Botulinum Toxin Market size was valued at USD 4.06 billion in 2021 and is predicted to reach USD 8.72 billion by 2030 with a CAGR of 8.3% from 2022-2030.

Botulinum toxin (BTX) is a type of toxin produced by a bacteria called clostridium botulinum, one of the most poisonous biological substances on earth. It acts as a neurotoxin, which is destructive to nerve tissues. This toxin was initially used to treat disorders such as blepharospasm, an abnormal contraction of the eyelid muscles and strabismus, a condition in which eyes do not line up with one another. It is the first biological toxin in the world that is licensed as a drug for treating diseases such as migraines, overactive bladder, and excessive sweating disorder. In addition, the cosmetic form of botulinum toxin, popularly known as Botox is widely used by cosmetic surgeons to reduce facial wrinkles and creases.

Market Dynamics and Trends:

Increasing demand of botulinum toxins such as Dysport and Jeuveau, in the cosmetic industry is driving the growth of botulinum toxin market. Dysport and Jeuveau are extensively used for skin revitalization due to their ability to reduce wrinkles by temporarily paralyzing facial muscles. Also, increasing cases of stress-triggered migraine and chronic cluster headaches across the globe that requires botulinum toxin for cure, are further driving the growth of the market. 

Moreover, upsurge in the therapeutic applications of botulinum toxin, have encouraged key market players such as Revance Therapeutics Inc, Merz Pharma, Ipsen, and Medy tox Inc to invest heavily in research and development. For instance, in 2020, Revance Therapeutics Inc. had invested USD 125.8 million in research and development of botulinum toxin related products.

However, side effects of botulinum toxin, such as pain, swelling or bruising at the injection site, and eye dryness or excessive tearing are restraining the growth of botulinum toxin market. Also, availability of non-regulated counterfeit botulinum products that compromises quality and sterility causes severe risk of botulinum toxin overdose and further restrain the market growth. On the contrary, development of new and advanced botulinum toxin products such as Meditoxin and METOX, that can be used for the treatment of hemifacial spasm, is expected to create ample growth opportunities for the market in the upcoming years.

Market Segmentations and Scope of the Study:

The botulinum toxin market is segmented on the basis of product, application, gender, age group, end-user, and geography. On the basis of product, the market is divided into toxin type A and toxin type B. On the basis of application, the market is classified into therapeutic and aesthetic. The therapeutic market is further sub-segmented into chronic migraine, spasticity, overactive bladder, cervical dystonia, blepharospasm, axillary hyperhidrosis, and others. On the basis of gender, the market is categorized into male and female. On the basis of age group, the market is divided into 13-19, 20-29, 30-39, 40-54, 55 and above. On the basis of end-user, the market is classified into hospitals, dermatology clinics, and spas & cosmetic centers. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America holds the lion share of the botulinum toxin market and is expected to dominate the market throughout the forecast period. This is attributed to factors such as high spending capacity and huge demand for aesthetic products and services among the population in this region. For instance, according to the American Society of Plastic Surgeons, nearly 15.6 million cosmetic procedures and 6.8 million reconstructive procedures has been performed in the United States in 2020 alone.

Asia-pacific is expected to show a steady rise in the botulinum toxin market due to the rapidly rising adoption of this toxin by the people in this region, along with increasing research and development initiatives by major market players such as Medy tox Inc. and Lanzhou Institute of Biological Products Co. Ltd. to expand the therapeutic applications of botulinum toxin. Also, rising concerns related to aesthetics such as lateral canthal lines and crow’s foot, are some of the major factors contributing to the growth of botulinum toxin market in the region.

Competitive Landscape:

The botulinum toxin market comprises of various market players such Abbvie Inc., Evolus Inc., Revance Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Merz Pharma, Ipsen, Medy tox Inc., Galderma, , Hugel Inc., US WorldMeds LLC., and Eisai Co. Ltd. These market players are aggressively conducting R&D, developing new products, and applying for government approvals and clearances to stay competitive and maintain their market positions. 

For instance, in August 2021, Merz Therapeutics announced that it had received approval from the European authorities for the use of Xeomin, a neurotoxin for the treatment of chronic sialorrhea (drooling) due to neurodevelopmental disorders that affect the development of the nervous system in children between 2 to 17 years of age. Moreover, in January 2020, a botulinum toxin product of Ipsen pharma Dysport, received a license update from U.K.’s medicine and healthcare products regulatory agency (MHRA). Dysport is used for treating muscle stiffness of upper limbs in children with cerebral palsy, a brain neurological disorder that causes problems with normal motor function that does not allow the body to move, talk or eat.

KEY BENEFITS:

• The botulinum toxin market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the botulinum toxin market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints and opportunities and their impact on the botulinum toxin market is provided in the report.

• The competitive analysis of the market players along with their market share in the botulinum toxin market

• The SWOT analysis and Porters Five Forces model is elaborated in the study.

• Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Product

• Toxin Type A

• Toxin Type B

By Application

• Therapeutic

  • Chronic Migraine

  • Spasticity

  • Overactive Bladder

  • Cervical Dystonia

  • Blepharospasm

  • Axillary Hyperhidrosis

  • Others

• Aesthetic

By Gender

• Male

• Female

By Age Group

• 13-19

• 20-29

• 30-39

• 40-54

• 55 and above

By End-User

• Hospitals

• Dermatology Clinics

• Spas & Cosmetic Centers

By Geography

• North America

  • U.S

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Netherlands

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Taiwan

  • Vietnam

  • Rest of Asia-Pacific

• RoW

  • Latin America

  • Middle East

  • Africa

REPORT SCOPE AND SEGMENTATION: